Data about treatment outcomes and toxicity in Latin America are scarce. There are differences with central countries based on access to healthcare system and socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction treatment of transplant eligible newly diagnosed multiple myeloma patients. Most common options are CyBorD (cyclophosphamide, bortezomib and dexamethasone) and VTD (bortezomib, thalidomide and dexamethasone). Main goal of our retrospective, multicentric study was to compare very good partial response rate (VGPR) or better after induction treatment in a real-world setting in Argentina. Secondary objectives included comparison of complete response (CR) post-induction and after bone marrow transplantation, grade 3-4 adverse events (AE), progression-free survival (PFS) and overall survival (OS). 322 patients were included (median age at diagnosis: 57 years; 52% male; 28% had ISS3; 14% with high risk cytogenetics; median follow-up: 34 months). CyBorD was indicated in 74% and 26% received VTD. In VTD arm, 72.62% of patients achieved at least VGPR vs 53.36% receiving CyBorD (OR: 1.96 [95%CI: 1.08-3.57; P = 0.026] after adjusting by age, ISS, LDH and cytogenetic risk). Difference in VGPR was 19.26% (95%CI: 15-24). CR rate were 35.92% (VTD) vs 22.55% (CyBorD) (adjusted OR: 2.13 [95%CI: 1.12-4.05]). Difference in CR was 13.37% (95%CI: 9.6-17.53). AEs were more common with VTD (69.05% vs 55.46% for CyBorD; P = 0.030), especially grade 3-4 neuropathy (P = 0.005) and thrombosis (P = 0.001). Thromboprophylaxis was inadequate in 20.24% of patients. Hematological AEs were more common with CyBorD, especially thrombocytopenia (P = 0.017). PFS and OS at 24 months were not different between treatments. In this real-world setting, VTD was associated with better CR and VGPR than CyBorD. Nevertheless, CyBorD continues to be the preferred induction regimen in Argentina, based on safety profile. Frontline ASCT improves quality of responses, especially in countries with limited access to new drugs. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.
February 17, 2020
Assesment of the influence of global and local exercises on core stabilisation mechanisms: randomised control trial.
July 30, 2020
March 19, 2020
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
ASCO 2019The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.